HT
ALNY icon

HAP Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History

HAP Trading’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,798
Closed -$3.76M – 666
2024
Q1 		$3.56M Buy
+23,798
New +$3.97M 0.41% 54
2023
Q4 		– Sell
-11,351
Closed -$2.01M – 950
2023
Q3 		$2.01M Buy
+11,351
New +$2.17M 0.32% 70

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HAP Trading's ALNY Position: Q2 2024 in Review

HAP Trading sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 23,798 shares — an estimated $3.76M sold.

HAP Trading first reported a position in ALNY in Q3 2023 and held it in 2 quarters. The position peaked at $3.56M in Q1 2024. 521 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • HAP Trading reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • HAP Trading sold 23,798 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $3.76M.
  • HAP Trading first reported a position in Alnylam Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • HAP Trading's Alnylam Pharmaceuticals position peaked at $3.56M in Q1 2024.
  • 521 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on HAP Trading's 13F filing for Q2 2024, filed 14 Aug 2024.